Adults (male or female) aged 18 years or older with a clinical diagnosis of prurigo nodularis (PN) for at least 6 months, may qualify to participate. Individuals must have nodular lesions on the upper limbs, trunk, and/or lower limbs with at least 20 nodules on the entire body, distributed bilaterally (on both sides). Moderate to severe disease must be present, as well as severe pruritus (itch).
Participants will receive investigational medication (active study drug) or placebo, via injection. Investigational medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.
At the end of the treatment period, individuals may be eligible to enter a long-term extension (LTE) study. As such, study participation could be 20 weeks and 6 visits to the study centre (if enter LTE) or 28 weeks and 7 visits to the study centre (for individuals who do not enter LTE).